Michel Beaugrand

Medicine · Health Sciences

67h-index25.8kcitations391works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(209), Hepatocellular Carcinoma Treatment and Prognosis(88), Liver Disease and Transplantation(70), Hepatitis C virus research(64), Hepatitis B Virus Studies(42)

Publications391 total

Perspective on This Article from Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis
2023Open Access
Data from Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis
2023Open Access
Data from Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis
2023Open Access
Perspective on This Article from Effect of Long-term Propranolol Treatment on Hepatocellular Carcinoma Incidence in Patients with HCV-Associated Cirrhosis
2023Open Access
Data from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Table 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Figures 1 - 2 from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Data from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Table 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Data from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Figure 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Figure 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Supplementary Figures 1 - 2 from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Data from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
2023Open Access
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis
Journal of Hepatology·2018· 120 citedOpen Access
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement
Alimentary Pharmacology & Therapeutics·2018· 51 citedOpen Access
Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan
Liver International·2017· 98 cited
Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography
Journal of Hepatology·2017· 1 cited
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
Journal of Hepatology·2016· 1.2k citedOpen Access
Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment—Long-term Results
Radiology·2016· 23 cited
page 1 of 20Next →

Frequent Co-authors

Jean–Claude Trinchet(21), Nathalie Ganne‐Carrié(20), Marianne Ziol(17), G. Nkontchou(12), Victor de Lédinghen(10), Patrick Marcellin(9), Dominique Roulot(7), Véronique Grando–Lemaire(7), Catherine Douvin(6), Pierre Nahon(6), Laurent Sandrin(4), Frédéric Mal(4), Christos Christidis(4), A. Kettaneh(4), Daniel Dhumeaux(4), M. Sasso(4), J.C. Trinchet(4), Dominique Pateron(4), Mounir Aout(4), Éric Vicaut(4)